FDA Approval Alert: The Need-to-Know | Ide-Cel in Previously Treated Multiple Myeloma

In April 2024, idecabtagene vicleucel was approved by the FDA for the treatment of relapsed/refractory multiple myeloma after at least 2 prior lines of therapy that included an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Results from the phase 3 KarMMa-3 trial of ide-cel vs standard of care in previously treated multiple myeloma led to the FDA approval.
FDA Approves Ide-Cel in Previously Treated Multiple Myeloma
Article
Apr 5, 2024 1:20 PM
Results from the phase 3 KarMMa-3 trial of ide-cel vs standard of care in previously treated multiple myeloma led to the FDA approval.